•   
  •   
  •   

World EU-Astra Vaccine Call Back On After Chaotic Morning in Dispute

16:11  27 january  2021
16:11  27 january  2021 Source:   msn.com

Asia Was a Model for How to Deal With COVID-19. Why Is It Lagging in Vaccine Rollouts?

  Asia Was a Model for How to Deal With COVID-19. Why Is It Lagging in Vaccine Rollouts? But most nations in the Asia-Pacific region, including South Korea, won't begin vaccinating citizens until February or March. New Zealand, another COVID-19 success story, won’t start vaccinating its healthcare workers until April. In the wealthy business hub of Singapore, just 6,000 people have received doses of the Pfizer-BioNTech vaccine since Dec. 30, out of a population of 5.7 million.Read More: A Year After COVID-19 Emerged, Asia Struggles to Contain Growing OutbreaksIt’s the deft handling of COVID-19 by many countries that has contributed to them becoming laggards in the vaccine race, experts say.

(Bloomberg) -- The clash between the European Union and drugmaker AstraZeneca Plc over Covid-19 vaccine delays temporarily descended into chaos on Wednesday before the two sides confirmed that a crunch call to resolve the standoff will take place.

Earlier on Wednesday, an EU official said the company had pulled out of the planned talks with the European Commission and government representatives. The official, who asked not to be named, said Astra executives had sent an email on Tuesday evening withdrawing “because there are too many moving parts.” The cancellation was disputed by Astra, and the EU subsequently said discussions were back on.

Teachers push back, churches in court, National Guard: News from around our 50 states

  Teachers push back, churches in court, National Guard: News from around our 50 states How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.

The contradictory statements were just the latest twist in a saga that erupted late last week when Astra warned of delays at a production plant in Belgium. That was followed by public disagreement over contract terms, accusations of blame, and even threats to put limits on vaccine exports. The latest confusion -- which pushed the life-and-death issue into the realm of farce -- is also an echo of the broader disorganization that’s marked the EU’s rollout of coronavirus shots so far.

a man wearing a suit and tie: AstraZeneca Plc CEO Pascal Soriot Interview © Bloomberg AstraZeneca Plc CEO Pascal Soriot Interview

Pascal Soriot

Photographer: Simon Dawson/Bloomberg

Iskra Reic, Astra’s Executive Vice-President for Europe and Canada, will take part in the meeting, where the EU wants to get more details about the delay to the rollout of shots. Governments are desperate to speed up the vaccination, as it’s proved sluggish so far, and also keen to avoid taking the blame.

Transit memorial, pen pals, White House doctor: News from around our 50 states

  Transit memorial, pen pals, White House doctor: News from around our 50 states How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.

The on-off status of the call emerged after Astra Chief Executive Pascal Soriot used an interview with European newspapers to deflect responsibility to the EU. He said the company has a so-called best-effort agreement that doesn’t specify a quantity. That’s because the EU insisted on receiving the AstraZeneca vaccine about the same time as the U.K. despite putting in its order three months later.

A key part of the disagreement is the use of vaccines produced in U.K. factories. Speaking on condition of anonymity, an EU official said that Soriot’s claim that the U.K. has priority on vaccines from British plants doesn’t exist in the contract.

The EU’s vaccination pace is lagging way behind the U.S. and the U.K. in terms of the share of its population inoculated, according to Bloomberg’s global tracker. Soriot said that once Astra gets EU regulatory approval -- expected within days -- it will ship at least 3 million doses immediately, with a target of 17 million by February.

Single-shot Johnson & Johnson vaccine 66 percent effective against moderate and severe illness

  Single-shot Johnson & Johnson vaccine 66 percent effective against moderate and severe illness A coronavirus vaccine that is easier to store and requires a single shot will soon be considered by regulators and could help bolster the nation’s limited supplies. The results, reported in a news release, put a third vaccine on the horizon in the United States — one with logistical advantages that could simplify distribution and expand access to shots in the United States and worldwide.

That should help Europe accelerate vaccinations and get economies closer to exiting damaging lockdowns that have crippled industries and caused growing discontent. Soriot suggested he understands that the situation is difficult for leaders across Europe, where Brussels has coordinated a vaccine-buying program.

“Everybody is getting kind of a bit, you know, aggravated or emotional about those things.” he said in the comments published in La Repubblica and other newspapers. “But I understand because the commission is managing the process for the whole of Europe.”

Read More: European Economy Lags Peers Amid Vaccine Shambles

In an effort to alleviate supply shortages, French drugmaker Sanofi said it has agreed to help produce more than 125 million doses of the shot Pfizer Inc. developed with Germany’s BioNTech SE. That shot, and one by Moderna Inc., are already authorized for use.

Sanofi will provide BioNTech access to its production sites in Frankfurt starting this summer, it said in a statement Wednesday. The goal is to accelerate efforts to package and distribute the vaccine, which needs to be kept at ultra-cold temperatures.

Read More:
Why Delaying the Second Covid Vaccine Shot Is Messy: QuickTakeEurope Is Flirting With a Vaccine Disaster: Ferdinando GiuglianoMoment of Truth Arrives for Vaccine Effect in Some Countries

For more articles like this, please visit us at bloomberg.com

©2021 Bloomberg L.P.

Shadow seekers, billionaire tax, vaccines for cabbies: News from around our 50 states .
How the COVID-19 pandemic is affecting every stateStart the day smarter. Get all the news you need in your inbox each morning.

usr: 0
This is interesting!